Smith & Nephew stock
SNNNYSESmith & Nephew plc, HealthcareISIN US83175M2052
67Score 67 out of 100, Neutral
Price and trend
66 / 100
Price history
−6.7% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 0.2% above it.
Since April 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 51).
The price is 16% below its 52-week high. Largest decline in 20 years: 58% (February 2020 to October 2023).
Chart figures for advanced users
- SMA 50$28.63
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$30.99
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)51
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$26.42
- The lowest closing price of the last twelve months.
- Resistance$36.90
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Smith & Nephew plc belongs to the Medical (Devices) industry (United Kingdom) and, with a market value of $12.99B, is number 15 of 90 companies in its industry on MEQIRI.
- This is an American depositary receipt (ADR).
- In fiscal 2025 it reported revenue of $6.16B (up 6.1% year on year) and earnings of $625M (up 51.7%).
Show more
- MEQIRI Score 67 out of 100 (Neutral): rank 189 of 714 in Healthcare, median 53.
- The P/E is 21 (Medical (Devices) median 29, own median of recent years 25.4).
- Our model puts fair value at $46.44, with the price 33% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Below fair valuePrice 33% below the fair value of $46.44.Valuation 74
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 86
- Reliable dividendNo dividend cut for 11 years.Capital allocation 57
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are fundamentals and valuation.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among smaller stocks.
From 2016 to 2025, 14 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What lowers it
- solid fundamentals
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $35.72 and expensive above $66.34 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $50.07 (cash-flow model) and $42.82 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 9.9%. At 10.9% the fair value would be $42.71, at 8.9% it would be $51.66.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (29).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 27 Jun 2026, revenue rose 6% on the twelve months before. Revenue has grown solidly since 2006, at about 4% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 68%, operating 13%, net 10%.
Debt & balance sheet
latest quarterModerate debt, and interest is adequately covered.
Earnings
- Next earnings
- 1 Mar 2027in 109 days
- Last reported
- 4 Aug 2026in line with expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- 2.19−0.1%
- Revenue
- $6.46B−0.1%
- Earnings per share
- 2.390.0%
- Revenue
- $6.8B−0.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook lowered
Share price after the results: −6.3%2026 underlying revenue growth guidance lowered to about 4% (second half 5% to 5.5%); profit and cash flow guidance maintained and expected savings raised from $150 million to $200 million.
“This includes an additional $50 million in efficiency savings that we identified for 2026, taking our total expected savings from $150 million to $200 million, and a broadly neutral impact from tariffs, net of refunds.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 4 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Smith & Nephew
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 67
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- Terumo4543.T $23.31B76
- Zimmer Biomet HoldingsZBH $20.34B68
- Sonova HoldingSOON.SW $20.24B74
- GlaukosGKOS $14.63B48
- PenumbraPEN $12.68B59
- Align TechnologyALGN $12.13B71
- Olympus7733.T $11.7B70
- DemantDEMANT.CO $11.62B73
ETFs that hold Smith & Nephew
Held by 6 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Vanguard FTSE Emerging Markets UCITS ETF (USD) AccumulatingVFEA | 0.01% | 0.17% | €5.24B |
| Vanguard FTSE All-World High Dividend Yield UCITS ETF (USD) AccumulatingVGWE | 0.00% | 0.29% | €13.67B |
| Vanguard FTSE All-World UCITS ETF (USD) AccumulatingVWCE | 0.00% | 0.14% | €79.59B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 14 Feb 2025)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.